Do analysts recommend DTSQ or KYTX?

Kyverna Therapeutics has a consensus price target of $29.00, suggesting a potential upside of 369.26%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kyverna Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has preferable earnings & valuation, DTSQ or KYTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Kyverna Therapeutics N/A N/A -$161.31M -$2.94 N/A

Is DTSQ or KYTX more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DT Cloud Star Acquisition N/A N/A N/A Kyverna Therapeutics N/A -81.92% -63.74%

Does the media refer more to DTSQ or KYTX?

In the previous week, Kyverna Therapeutics had 3 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 1 mentions for DT Cloud Star Acquisition. Kyverna Therapeutics' average media sentiment score of 0.20 beat DT Cloud Star Acquisition's score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DT Cloud Star Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend DTSQ or EIKN?

Eikon Therapeutics has a consensus price target of $25.00, indicating a potential upside of 233.33%. Given Eikon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Eikon Therapeutics is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eikon Therapeutics 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation and earnings, DTSQ or EIKN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A

Is DTSQ or EIKN more profitable?

Company Net Margins Return on Equity Return on Assets DT Cloud Star Acquisition N/A N/A N/A Eikon Therapeutics N/A N/A N/A

Do analysts rate DTSQ or AVTE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, DTSQ or AVTE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is DTSQ or AVTE more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DT Cloud Star Acquisition N/A N/A N/A Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts prefer ZURA or DTSQ?

Zura Bio currently has a consensus price target of $17.00, suggesting a potential upside of 311.62%. Given Zura Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Zura Bio is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zura Bio 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, ZURA or DTSQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.13 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is ZURA or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -56.13% -50.15% DT Cloud Star Acquisition N/A N/A N/A

Does the media favor ZURA or DTSQ?

In the previous week, Zura Bio had 3 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Zura Bio and 1 mentions for DT Cloud Star Acquisition. Zura Bio's average media sentiment score of 0.20 beat DT Cloud Star Acquisition's score of 0.00 indicating that Zura Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DT Cloud Star Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DTSQ or RZLT?

Rezolute has a consensus price target of $11.22, suggesting a potential upside of 141.86%. Given Rezolute's stronger consensus rating and higher possible upside, analysts clearly believe Rezolute is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rezolute 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.79

Which has preferable earnings and valuation, DTSQ or RZLT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Rezolute N/A N/A -$77.59M -$0.76 N/A

Is DTSQ or RZLT more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets DT Cloud Star Acquisition N/A N/A N/A Rezolute N/A -62.99% -57.94%

Does the media refer more to DTSQ or RZLT?

In the previous week, Rezolute had 16 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 17 mentions for Rezolute and 1 mentions for DT Cloud Star Acquisition. Rezolute's average media sentiment score of 0.38 beat DT Cloud Star Acquisition's score of 0.00 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DT Cloud Star Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 2 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

DT Cloud Star Acquisition (DTSQ) Competitors

$11.51 +0.03 (+0.25%)

Closing price 03:50 PM Eastern

Extended Trading

$11.51 +0.00 (+0.01%)

As of 07:30 PM Eastern

Compare

DTSQ vs. KYTX, EIKN, AVTE, ZURA, and RZLT

Should you buy DT Cloud Star Acquisition stock or one of its competitors? DT Cloud Star Acquisition's main competitors and comparable companies include Kyverna Therapeutics (KYTX), Eikon Therapeutics (EIKN), Aerovate Therapeutics (AVTE), Zura Bio (ZURA), and Rezolute (RZLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DT Cloud Star Acquisition compare to Kyverna Therapeutics?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

DT Cloud Star Acquisition has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market.

18.1% of Kyverna Therapeutics shares are held by institutional investors. 52.9% of DT Cloud Star Acquisition shares are held by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DT Cloud Star Acquisition's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Kyverna Therapeutics	N/A	-81.92%	-63.74%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

Kyverna Therapeutics has a consensus price target of $29.00, suggesting a potential upside of 369.26%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Kyverna Therapeutics had 3 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 1 mentions for DT Cloud Star Acquisition. Kyverna Therapeutics' average media sentiment score of 0.20 beat DT Cloud Star Acquisition's score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DT Cloud Star Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Kyverna Therapeutics beats DT Cloud Star Acquisition on 8 of the 11 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Eikon Therapeutics?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than Eikon Therapeutics. MarketBeat recorded 1 mentions for DT Cloud Star Acquisition and 0 mentions for Eikon Therapeutics. DT Cloud Star Acquisition's average media sentiment score of 0.00 equaled Eikon Therapeutics'average media sentiment score.

Company	Overall Sentiment
DT Cloud Star Acquisition	Neutral
Eikon Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Eikon Therapeutics	N/A	N/A	N/A

Eikon Therapeutics has a consensus price target of $25.00, indicating a potential upside of 233.33%. Given Eikon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Eikon Therapeutics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Eikon Therapeutics beats DT Cloud Star Acquisition on 4 of the 5 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Aerovate Therapeutics?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

DT Cloud Star Acquisition has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

DT Cloud Star Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for DT Cloud Star Acquisition and 0 mentions for Aerovate Therapeutics. DT Cloud Star Acquisition's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
DT Cloud Star Acquisition	Neutral
Aerovate Therapeutics	Neutral

Summary

DT Cloud Star Acquisition beats Aerovate Therapeutics on 4 of the 5 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Zura Bio?

Zura Bio (NASDAQ:ZURA) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

DT Cloud Star Acquisition's return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
DT Cloud Star Acquisition	N/A	N/A	N/A

Zura Bio has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Zura Bio currently has a consensus price target of $17.00, suggesting a potential upside of 311.62%. Given Zura Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Zura Bio is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Zura Bio had 3 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Zura Bio and 1 mentions for DT Cloud Star Acquisition. Zura Bio's average media sentiment score of 0.20 beat DT Cloud Star Acquisition's score of 0.00 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DT Cloud Star Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.1% of Zura Bio shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Zura Bio beats DT Cloud Star Acquisition on 8 of the 11 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Rezolute?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

DT Cloud Star Acquisition's return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Rezolute	N/A	-62.99%	-57.94%

83.0% of Rezolute shares are held by institutional investors. 52.9% of DT Cloud Star Acquisition shares are held by company insiders. Comparatively, 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Rezolute had 16 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 17 mentions for Rezolute and 1 mentions for DT Cloud Star Acquisition. Rezolute's average media sentiment score of 0.38 beat DT Cloud Star Acquisition's score of 0.00 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DT Cloud Star Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A

Rezolute has a consensus price target of $11.22, suggesting a potential upside of 141.86%. Given Rezolute's stronger consensus rating and higher possible upside, analysts clearly believe Rezolute is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rezolute	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

DT Cloud Star Acquisition has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Summary

Rezolute beats DT Cloud Star Acquisition on 7 of the 10 factors compared between the two stocks.

Get DT Cloud Star Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTSQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTSQ vs. The Competition

Export

Metric	DT Cloud Star Acquisition	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$102.18M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	20.71%
P/E Ratio	N/A	13.42	274.13	26.16
Price / Sales	N/A	1,225.48	587.04	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	N/A	17.17	11.21	6.34
Net Income	N/A	-$22.69M	$3.50B	$381.90M
7 Day Performance	-0.35%	-1.20%	-0.84%	-1.39%
1 Month Performance	1.18%	-9.68%	-5.42%	-4.31%
1 Year Performance	9.60%	10.09%	4.38%	-0.35%

DT Cloud Star Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTSQ DT Cloud Star Acquisition	0.7173 of 5 stars	$11.51 +0.3%	N/A	+9.7%	$102.18M	N/A	N/A	3	News Coverage
KYTX Kyverna Therapeutics	2.2832 of 5 stars	$6.22 -4.6%	$29.00 +366.2%	-13.9%	$403.22M	N/A	N/A	149
EIKN Eikon Therapeutics	2.5327 of 5 stars	$7.33 -1.1%	$25.00 +241.1%	N/A	$401.36M	N/A	N/A	384
AVTE Aerovate Therapeutics	N/A	$13.77 -2.0%	N/A	+52.3%	$399.12M	N/A	N/A	20	High Trading Volume
ZURA Zura Bio	2.6132 of 5 stars	$4.11 -0.7%	$17.00 +313.6%	-4.8%	$396.73M	N/A	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTSQ) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DT Cloud Star Acquisition (DTSQ) Competitors

DTSQ vs. KYTX, EIKN, AVTE, ZURA, and RZLT

How does DT Cloud Star Acquisition compare to Kyverna Therapeutics?

Summary

How does DT Cloud Star Acquisition compare to Eikon Therapeutics?

Summary

How does DT Cloud Star Acquisition compare to Aerovate Therapeutics?

Summary

How does DT Cloud Star Acquisition compare to Zura Bio?

Summary

How does DT Cloud Star Acquisition compare to Rezolute?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTSQ vs. The Competition

DT Cloud Star Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DT Cloud Star Acquisition (DTSQ) Competitors

DTSQ vs. KYTX, EIKN, AVTE, ZURA, and RZLT

How does DT Cloud Star Acquisition compare to Kyverna Therapeutics?

Which has more volatility and risk, DTSQ or KYTX?

Do insiders & institutionals have more ownership in DTSQ or KYTX?

Is DTSQ or KYTX more profitable?

Which has preferable earnings & valuation, DTSQ or KYTX?

Do analysts recommend DTSQ or KYTX?

Does the media refer more to DTSQ or KYTX?

Summary

How does DT Cloud Star Acquisition compare to Eikon Therapeutics?

Which has better valuation and earnings, DTSQ or EIKN?

Does the media favor DTSQ or EIKN?

Is DTSQ or EIKN more profitable?

Do analysts recommend DTSQ or EIKN?

Summary

How does DT Cloud Star Acquisition compare to Aerovate Therapeutics?

Do analysts rate DTSQ or AVTE?

Which has more risk and volatility, DTSQ or AVTE?

Which has better earnings & valuation, DTSQ or AVTE?

Is DTSQ or AVTE more profitable?

Does the media favor DTSQ or AVTE?

Summary

How does DT Cloud Star Acquisition compare to Zura Bio?

Which has preferable earnings & valuation, ZURA or DTSQ?

Is ZURA or DTSQ more profitable?

Which has more volatility & risk, ZURA or DTSQ?

Do analysts prefer ZURA or DTSQ?

Does the media favor ZURA or DTSQ?

Do institutionals & insiders have more ownership in ZURA or DTSQ?

Summary

How does DT Cloud Star Acquisition compare to Rezolute?

Is DTSQ or RZLT more profitable?

Do insiders & institutionals have more ownership in DTSQ or RZLT?

Does the media refer more to DTSQ or RZLT?

Which has preferable earnings and valuation, DTSQ or RZLT?

Do analysts prefer DTSQ or RZLT?

Which has more risk and volatility, DTSQ or RZLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTSQ vs. The Competition

DT Cloud Star Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools